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Extracts of seventeen Salvia species used in traditional medicine in South Africa were subjected to biological testing. The potential ability to
inhibit the in vitro growth/proliferation of Plasmodium falciparum (FCR-3 strain) and the cytotoxic effects on three human cancer cells [breast
adenocarcinoma (MCF-7), colon adenocarcinoma (HT-29) and glioblastoma (SF-268)] and a human kidney epithelial cell line were investigated.
The extracts displayed antimalarial activity with IC50 values ranging from 3.91 to 26.01 μg/ml and S. radula displaying the most favorable
activity. Two compounds were subsequently isolated from the active fraction of S. radula and identified as betulafolientriol oxide and salvigenin.
The two compounds displayed similar or lower antimalarial activity (IC50 values: 4.95 and 24.60 μg/ml, respectively) compared to the crude
solvent extract. The concentration required to inhibit 50% of cancer cells ranged between 9.69 μg/ml and 43.65 μg/ml, and between 8.72 μg/ml
and 59.12 μg/ml against the MCF-7 and SF-268 cell lines, respectively. The IC50 values determined for the HT-29 cell line ranged from 17.05 to
57.00 μg/ml, with S. lanceolata being the most active. The samples also displayed some degree of toxicity when tested against the human kidney
epithelial cells, with IC50 values ranging from 12.12 to 53.34 μg/ml. The in vitro antimalarial and anticancer activities support the historic and
present use of Salvia species in traditional medicine.
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Many studies have been carried out on the antimalarial and
anticancer activities of various plant species with some
encouraging results (e.g. Schwikkard and Van Heerden, 2002;
Boik, 2001). Two of the most potent antimalarial drugs
originated from plants; quinine from Cinchona and artemisinin
from Artemisia annua (Gessler et al., 1994). Plants have a
reputable history of use in the treatment of cancer. In a review
by Hartwell (1982), more than 3000 plant species are listed that
have reportedly been used in the treatment of cancer, but in
many instances, the “cancer” is undefined (Cragg and Newman,
2005). Over 60% of currently used anticancer agents are derived
in one way or another from natural sources including plants,⁎ Corresponding author. Tel.: +27 12 382 6360; fax: +27 12 382 6243.
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0254-6299/$ - see front matter © 2007 SAAB. Published by Elsevier B.V. All righ
doi:10.1016/j.sajb.2007.08.001marine organisms and micro-organisms (e.g. paclitaxel, topo-
tecan and irinotecan) (Cragg et al., 1997; Cragg and Newman,
2005).
In South Africa, reports on plants used for the treatment of
cancer are rare, and can be ascribed to a complex set of signs and
symptoms associated with the disease (Steenkamp and Gouws,
2006). With this in mind, it is recommended that when selecting
plants for potential anticancer activity, ethnopharmacological
properties such as immune, inflammatory and skin disorders
should be considered (Cordell et al., 1991; Popoca et al., 1998).
Salvia species have been used in traditional medicines in
China, South Africa and many other countries against various
infectious and inflammatory diseases and to treat malaria, hard
swellings, abscesses, calluses, warts or cancer (Watt and Breyer-
Brandwijk, 1962; Ulubelen et al., 1999; Shoemaker et al.,
2005). In our previous investigation, we demonstrated that the
essential oils of indigenous Salvia species exhibited variousts reserved.
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and antibacterial activities (Kamatou et al., 2005, 2006). In a
continuation to verify the efficacy of traditional medicines used
in South Africa, the antimalarial and anticancer activities of the
solvent extracts of seventeen Salvia species were investigated.
2. Materials and methods
2.1. Plant material
The aerial parts of 17 Salvia species were collected from
various localities in South Africa between December 2003 and
December 2004, predominantly from the Cape region (Table 1).
The identity of each species was confirmed by the South
African National Biodiversity Institute (Pretoria) and voucher
specimens were deposited in the Department of Pharmaceutical
Sciences, Tshwane University of Technology, Pretoria, South
Africa. The air-dried plant material was ground to a fine
powder, extracted with a mixture of methanol and chloroform
(1:1, v/v) and the solvent evaporated under vacuum at 70 °C.
2.2. Preparation of samples
Stock solutions of the solvent extracts and reference
compounds [5′-fluorouracil (Merck), chloroquine diphosphate
(Sigma), quinine sulfate (Fluka)] were prepared in dimethyl
sulfoxide (Saarchem) at a concentration of 10 mg/ml and stored
at −20 °C. The dilutions were prepared with appropriate ex-
perimental medium on the day of the experiment.Table 1
The IC50 values (mean±S.D., μg/ml) of antimalarial activity and cytotoxic effects o
Species Location Antimalarial activity (n=3)
S. africana-caerulea SWCa 22.68±2.80
S. africana-lutea SWCa 15.86±5.04
S. albicaulis KBGb 15.83±1.94
S. aurita KBGb 8.92±2.63
S. chamelaeagnea KBGb 8.71±1.96
S. disermas KBGb 24.17±4.10
S. dolomitica Ex Manning 7.62±1.44
S. garipensis KBGb 13.95±3.76
S. lanceolata SWCa 26.01±2.95
S. muirii KBGb 11.87±2.13
S. namaensis Swartberg 25.38±2.11
S. radula Road to Derby 3.91±0.52
S. repens KBGb 8.25±2.09
S. runcinata Klerkskraal Dam 16.61±3.33
S. schlechteri KBGb 17.51±2.05
S. stenophylla East of Clarens 6.50±1.37
S. verbenaca De Rust 23.97±1.10
5′-FU –
Chloroquine 0.06±0.01
Quinine 0.14±0.03
Betulafolientriol oxide (1) 4.95±2.00 c
Salvigenin (2) 24.60±1.38 c
nc: IC50 values not calculated because the percentage inhibition at 100 μg/ml was l
a SWC: South Western Cape.
b KBG: Kirstenbosch Botanical Garden.
c Mean±s.e. (n=1) due to the small quantity of the isolated compound.2.3. In vitro maintenance of Plasmodium falciparum and the
antimalarial assay
The chloroquine-resistant P. falciparum FCR-3 strain was
continuously cultured according to the procedure described by
Trager and Jensen (1976) with modifications as described by
Van Zyl and Viljoen (2002). The antiplasmodial activity was
assessed using the [3H]-hypoxanthine method (Desjardins et al.,
1979; Van Zyl and Viljoen, 2002) against a single cycle (48 h)
of growth. Dilutions of the test samples were plated out in
triplicate in a 96-well plate before parasitized red blood cells
(0.5% parasitaemia and 1% haematocrit) were added and
incubated for 24 h at 37 °C in a candle jar. The [3H]-hypoxanthine
(Amersham) was then added to the plate and incubated for a
further 24 h. The amount of the [3H]-hypoxanthine incorporated
into the parasite DNA was determined with beta scintillation
counting (Wallac®). The inhibitory concentration which
killed 50% of parasites as indicated by the in vitro uptake
of [3H]-hypoxanthine (IC50 value) was calculated. Chloro-
quine diphosphate and quinine sulphate were used as refer-
ence antimalarial drugs.
2.4. In vitro cancer cell line maintenance and sulforhodamine
B assay
Cells lines representing the most common human cancers
(WHO, 2006) were obtained from the National Cancer Institute
(NCI). These included the breast adenocarcinoma (MCF-7), the
glioblastoma (SF-268) and the colon adenocarcinoma (HT-29).f solvent extracts of indigenous Salvia species
Cytotoxic effects on various human cell lines (n=3)
HT-29 MCF-7 SF-268 Kidney cells
27.10±1.08 23.36±4.20 8.72±1.52 14.38±3.39
20.00±3.41 43.65±8.38 nc 25.01±1.94
25.33±1.11 35.25±5.66 27.50±0.89 37.29±0.58
24.58±6.41 17.28±1.71 44.87±2.48 28.31±4.94
29.53±5.14 18.12±1.67 34.98±4.07 24.76±7.60
26.87±0.57 38.56±1.28 59.12±2.75 53.34±3.90
nc 37.05±2.10 nc 40.26±9.07
nc 39.44±3.90 nc 42.44±3.03
17.05±3.50 26.15±2.15 nc 26.71±6.41
55.63±1.30 39.07±2.86 nc 37.00±5.41
24.39±3.42 36.36±3.07 nc 21.91±2.89
32.10±2.93 9.69±0.92 27.55±4.52 20.12±4.02
43.62±5.17 23.36±2.16 nc 23.24±4.72
55.37±2.10 43.42±5.46 nc 22.00±3.75
57.00±11.67 18.37±0.47 54.40±4.42 28.16±4.69
17.41±2.65 23.74±1.96 43.86±3.43 12.12±2.02
50.04±5.39 31.50±13.70 nc 20.85±2.59
7.00±2.02 1.11±0.31 nc N100
– – – N100
– – – N100
– – – N100
– – – N100
ess than 80%. –: not determined.
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DMEM (Highveld Biological) culture medium and supplemen-
ted with 10% fetal bovine serum.
The colourimetric sulforhodamine B (SRB) assay was
performed according to Monks et al. (1991) and Wu et al.
(1993). Cells were seeded at 15000 cells/well and incubated for
24 h. Thereafter, different sample dilutions were added to the
appropriate microtitre wells and the plate incubated for a further
48 h. At the end of the 48 h incubation period, cells were fixed
with 50% (w/v) trichloroacetic acid (TCA; Saarchem) for 1 h at
4 °C. TCA-fixed cells were stained with 0.4% (w/v) SRB
solution (Sigma®) for 10 min at room temperature. Bound dye
was solubilised with 10 mM tris (hydroxymethyl) amino-
methane (Merck) and the absorbance was read at 492 nm against
a tris (hydroxymethyl) aminomethane blank on an automated
spectrophotometer plate reader (Labsystems iEMS reader MF)
connected to the Ascent® version 2.4 software. 5′-Fluorouracil
(5′-FU) was used as positive control.
2.5. In vitro maintenance of human kidney cells and the 3-[4,5-
dimethylthiazol-2-yl]-2,5- diphenyltetrazolium bromide assay
The 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium
bromide (MTT, USB) colourimetric assay was performed on
transformed human kidney (Graham) cells according to
Mosmann (1983), Van Zyl and Viljoen (2002). Cells were
seeded at 45000/well and exposed to test extracts at 37 °C for
44 h. The MTT solution (0.5%, w/v) was then added and the
plate incubated for a further 4 h before the absorbance was read
at the test wavelength of 540 nm and 690 nm (as a reference)
using a spectrophotometer plate reader (Labsystems iEMS
reader MF) connected to the Ascent® version 2.4 software. The
toxicity of the plant extracts was compared to 5′-FU.
2.6. Isolation of compounds by column chromatography
As S. radula exhibited the best antimalarial activity among
the plants screened, it was selected for the bioassay-guided
isolation of the active compound(s). The residue obtained
(22.4 g) from the methanol/chloroform extract (1:1; v/v) was
mixed with silica 60 (0.063–0.2 mm/70–230 mesh ASTM),
dried to a fine powder. The extract was eluted with hexane:
dichloromethane (9:1), dichloromethane:methanol (6:1) and
finally with 100% methanol. Five fractions were collected and
tested for antimalarial activity. Fraction 3 (12.5 g) was found to
display the best activity and was selected for further
purification. It was re-chromatographed with toluene:ethyl
acetate (10:3). A total number of 222 subfractions in 3 ml test
tubes were collected and spotted onto a TLC plate developed in
with toluene:ethyl acetate (10:3). The separated spots were
viewed under UV (254 nm and 366 nm) and also sprayed with
0.5% anisaldehyde (v/v) sulfuric acid reagent (Fluka®) in
glacial acetic acid:methanol:sulfuric acid (10:85:5). Subfrac-
tions with similar Rf values were combined and concentrated to
afford 7 major fractions (1–7). Two of the major fractions were
selected based on the results of their biological activity. Fraction
3 eluted with toluene:ethyl acetate (10:3) resulted in theisolation of compound 1 (29.4 mg). Compound 2 (24.1 mg)
was obtained after repeated column chromatography of fraction
5 with toluene:ethyl acetate (10:2). The structures of the two
compounds were determined using the 1H NMR and 13C NMR
data recorded on a Varian Inova 2000, 300 MHz spectrometer.
All spectra were recorded at 25 °C in deuterated chloroform and
the chemical shifts were recorded in ppm referenced to
tetramethylsilane (TMS). Electron ionization MS of the isolated
compounds were performed by direct inlet at 70 eV on a GC–
MS QP 2010 gas chromatography–mass spectrometer. Struc-
tures were confirmed by comparison of the 1H NMR and 13C
NMR data of the isolated compounds with literature values
(Voirin, 1983; Harraz et al., 1995; Rouf et al., 2001).
2.7. Data analysis
The IC50 values (concentration at which 50% of cells/
parasites were killed) are reported as mean±standard deviation
of three independent experiments. The IC50 values against the
human cancer cell lines were only calculated for the solvent
extracts exhibiting at least 80% inhibition when tested at a
concentration of 100 μg/ml. One-way analysis of variance
(ANOVA) and Student t-tests were used to compare data using
Statistica version 5.0 software at a 95% confidence limit. A
correlation between the anticancer activity and toxicity profile
was assessed using Pearson's correlation coefficient.
3. Results and discussion
3.1. The antimalarial activity of Salvia species
The in vitro inhibitory effects of the Salvia extracts against
the chloroquine-resistant P. falciparum (FCR-3) are shown in
Table 1. The antimalarial activity of the extracts (IC50 values)
ranged from 3.91±0.52 to 26.01±2.95 μg/ml, with the extract
of S. radula being the most active ( pb0.05). One-way analysis
of variance showed that there was no difference in the
antimalarial activity of the extracts of S. aurita, S. chamelaeag-
nea, S. dolomitica, S. muirii, S. repens and S. stenophylla
( pN0.05). Similarly, the activity of S. africana-lutea,
S. albicaulis, S. garipensis, S. runcinata and S. schlechteri did
not differ ( pN0.05). The extract of S. africana-caerulea,
S. disermas, S. lanceolata, S. namaensis and S. verbenaca
also exhibited comparable activity ( pN0.05). All the extracts
were less potent than the two antimalarial reference drugs
chloroquine diphosphate and quinine sulfate ( pb0.05).
In this study, the solvent extracts from Salvia species
exhibited antimalarial properties against the chloroquine-
resistant P. falciparum FCR-3 strain, with all IC50 values
lower than 30 μg/ml. Clarkson et al. (2004) also demonstrated
that S. repens displayed antimalarial activity against the
chloroquine-sensitive D10 strain of P. falciparum (IC50 value:
10.8 μg/ml) using the pLDH assay, which is similar to that
reported in the current study (IC50 value: 8.25±2.09 μg/ml).
The isolated compounds from S. radula and the presence of
betulafolientriol oxide (IC50 value: 5 μg/ml) in all the investigated
species (Kamatou, 2006), may have contributed to the overall
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due to betulafolientriol oxide acting alone or in combination with
other compounds present in the solvent extract.
3.2. Identification, characterisation and antimalarial activity of
the isolated compounds
Compound 1 was isolated as a white powder. From the mass
spectrum, compound 1 has an M+ at m/z 476, which corre-
sponds to a molecular formula of C30H52O4. This compound, a
diterpene, was identified as betulafolientriol oxide. Compound
2 was isolated as a yellow powder and was identified as 5-
hydroxy-6,7,4′-trimethoxyflavone (salvigenin), with a molecu-
lar formula of C18H16O6. The structures of the two compounds
are presented in Fig. 1. The two isolated compounds were tested
for antimalarial activity. Betulafolientriol oxide exhibited the
best activity compared to the flavonoid (salvigenin), with 4.95±
2.00 μg/ml killing 50% of parasites (Table 1). The two
compounds exhibited comparable or lower antimalarial activity
than the solvent extract of S. radula and the reference
antimalarial drugs (Table 1). In theory, fractionation leading
to the isolation of individual compounds should result in
aliquots having higher activity than the original extract.
However, in this study, the activity of the isolated compounds
was not greater than that of the crude extract. This loss of
activity may be explained by the possibility of decomposition of
the active compounds during the fractionation procedure
(Houghton et al., 2007). Decomposition of constituents to less
active substances may take place due to the reaction with
solvents used. The loss of activity may also be due to the fact
that synergy might account for the better activity of mixture
than isolated compounds. This has been claimed by many
herbalists, but it is only recently that it has received much
scientific attention, partly because it is now possible to
demonstrate it experimentally (Houghton et al., 2007).
3.3. Anticancer activity of Salvia species
The inhibition of tumour cell proliferation by the solvent
extracts of the 17 indigenous Salvia species investigated are
displayed in Table 1. All the extracts were significantly lessFig. 1. Structures of compoundpotent than 5′-FU (pb0.05). The best cytotoxic activity against
the HT-29 cell line was obtained with the extracts of S.
lanceolata (IC50 value: 17.05±3.50 μg/ml); S. stenophylla
(IC50 value: 17.41±2.65 μg/ml) and S. africana-lutea (IC50
value: 20.00±3.41 μg/ml), S. aurita (IC50 value: 24.58±
6.41 μg/ml) and S. namaensis (IC50 value: 24.39±3.42 μg/ml),
showed no significant difference in their activity ( pN0.05).
Six species, viz. S. africana-caerulea, S. albicaulis, S. aurita,
S. chamelaeagnea, S. disermas and S. namaensis, did not
differ significantly from one another in their inhibitory effects
( pN0.05).
S. radula exhibited the most favourable activity (IC50 value:
9.69±0.92 μg/ml) ( pb0.05), while S. africana-lutea and
S. runcinata were among the least active against the MCF-7
cells (Table 1). Two species, S. dolomitica and S. garipensis,
showed a degree of selectivity, as they were not active against
the HT-29 (IC50 valueN100 μg/ml) and SF-268 (IC50
valueN100 μg/ml) cell lines, but active against the MCF-7
cell line (IC50 valueb39 μg/ml) (Table 1).
In contrast, S. africana-caerulea, with an IC50 value of 8.72±
1.52 μg/ml, was the most active extract against the SF-268 cells
( pb0.05). The cell proliferative inhibition by S. africana-lutea,
S. dolomitica, S. garipensis, S. lanceolata, S.muirii, S. namaensis,
S. repens, S. runcinata and S. verbenaca tested at a concentration
of 100μg/ml exhibited less than 80% inhibition of the cell growth.
The IC50 values were thus not calculated for these species
(Table 1). The IC50 values of nearly all the species were above
30 μg/ml. No significant difference in the activity of S. albicaulis
and S. radula against the SF-268 cells ( pN0.05) was observed.
Treatments with Salvia extracts resulted in growth inhibition
in the majority of cases. For the three cell lines examined, MCF-
7 cells were the most sensitive, as it was inhibited by all the
solvent extracts, while the SF-268 cell line was the least
sensitive with approximately 53% (9/17) of the samples
exhibiting less than 80% inhibition at 100 μg/ml (Table 1).
In the screening of the anticancer activity of plants, species
which need to be considered for further analysis are those that
show activity against certain cell lines and are not toxic to
others. In this study, cell line selectivity was observed. The
solvent extracts of S. dolomitica, S. garipensis, S. lanceolata,
S. muirii, S. namaensis, S. repens, S. runcinata and S. verbenacas isolated from S. radula.
242 G.P.P. Kamatou et al. / South African Journal of Botany 74 (2008) 238–243showed some degree of activity against MCF-7, but were,
however, not active against the SF-268 and/or HT-29 cell lines
(Table 1).
The solvent extracts also exhibited varying degrees of toxicity
against the human kidney epithelial cells with the IC50 values
ranging from 12.12±2.02 μg/ml to 53.34±3.90 μg/ml. The
solvent extracts of S. africana-caerulea and S. stenophylla were
similar ( pN0.05) and were the most toxic, while S. disermas
was the least toxic in comparison to the other extracts
( pb0.05). The 5′-FU was significantly less toxic than all the
solvent extracts ( pb0.05) with the safety indices indicating
the solvent extracts being 3 to 11 times more toxic than 5′-FU.
The isolated compounds, namely betulafolientriol oxide and
salvigenin from S. radula exhibited low toxicity against the
human kidney epithelial cells, with IC50 values greater than
100 μg/ml.
In this study, there may be compounds in Salvia species
extracts that can induce a cytotoxic action against various
cancer cell lines and initiate cell death. The American National
Cancer Institute guidelines set the limit of activity for crude
extracts at a 50% inhibition (IC50 value) of proliferation of less
than 30 μg/ml (Suffiness and Pezzuto, 1990). The plants
exhibited various responses depending on the cell line used. The
percentage of plant extracts with IC50 values less than 30 μg/ml
was 17, 47 and 53% against the SF-268, MCF-7 and HT-29
cells, respectively. S. africana-caerulea was the only species
that exhibited anticancer activity against all three cell lines, with
an IC50 value of less than 30 μg/ml (Table 1).
The extract of S. hypargeia has been investigated by
Ulubelen et al. (1999) against a panel of cell lines, including
the human colon cells (COL-2), breast cancer cells (BC-1) and
lung cancer cells (LU-1). Results indicated that the plant
possesses anticancer activity with IC50 valuesb20 μg/ml, which
in general, were lower than those obtained in this study when
tested against the MCF-7 breast cancer cell line (Table 1).
Flavonoids are biosynthesised by plants and have strong
anti-oxidant activity for scavenging free radicals which are
involved in cell damage and tumour promotion. Indigenous
Salvia species also possess flavonoids (Kamatou, 2006) and the
presence of flavonoids may have contributed to their anticancer
activity. The flavonoid isolated from S. radula (salvigenin) was
tested against the MCF-7 cells and it exhibited moderate activity
(IC50 value: 67.78±3.78 μg/ml), although not significantly
comparable to the activity of 5′-FU. Testing could not be
conducted on the HT-29 and SF-268 cell lines as the amount of
flavonoid isolated was limited.
Many alkaloids are poisonous to both animals and humans.
Some of the species investigated, such as S. chamelaeagnea,
S. namaensis and S. runcinata, tested positive for alkaloids
(Raffauf, 1996). A poor correlation between the anticancer
activity and the toxicity of the extracts was observed. It was,
however, interesting to note that the extracts of S. lanceolata,
S. radula and S. stenophylla displaying anticancer activity, also
exhibited some degree of toxicity. In these cases, it could be
speculated that the same compound(s) may be responsible for
both the anticancer activity and the “general” toxicity profile of
the solvent extracts.This is the first extensive in vitro investigation on the
antimalarial and anticancer activities of indigenousSalvia species.
The investigated species have shown their ability to inhibit
cellular proliferation of three different types of human cancer.
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